Daewoong Pharmaceutical Co., Ltd.

Inwoo Kim

Ji Duck Kim

In Young Lee

Sun Ah Jun

Hyae Jung Hyun

Hong-Chul Yoon

Myunggi Jung

Hyo Shin Kim

Seong Hee Cho

Hyung Geun Lee

Min Jae Cho

Eunkyung Park

The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).

Sodium channel blockers

The present invention relates to a novel benzoxazine benzimidazole derivative of formula (1) as an antagonist against a vanilloid receptor-1, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The benzoxazine benzimidazole derivative of the present invention may be useful for preventing or treating a disease associated with antagonistic activity of vanilloid receptor-1: 

Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof

Growing community of inventors

Seoul, South Korea

Inwoo Kim